New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
11:57 EDTBVX, SYK, HART, ISRGIntuitive Surgical falls after guidance disappoints
Shares of Intuitive Surgical (ISRG), which makes and markets the da Vinci Surgical System, are falling after the company announced it would sell fewer systems in 2014 compared to the prior year. It also declined to provide revenue guidance for 2014. WHAT'S NEW: Last night, Intuitive Surgical reported Q4 EPS of $4.28 and revenue of $576.2M, both of which exceeded expectations of $3.83 and $558.46M, respectively. WHATíS NOTABLE: On the companyís Q4 earnings conference call, management said the company would likely sell fewer da Vinci systems in 2014 compared to 2013. It forecast 2014 procedures increasing 9%-12%, compared to a 16% increase in procedures for 2013. The company declined to provide revenue guidance for 2014, citing a lack of visibility. ANALYST REACTION: This morning, research firm Jefferies said the companyís outlook was conservative. Jefferies said that while Intuitive Surgical's lack of revenue and earnings guidance was indicative of near-term headwinds and uncertainties, its procedure guidance met expectations and was likely conservative. The firm said Intuitive's long-term growth prospects remained compelling, and it kept a Buy rating on the stock with a $480 price target. PRICE ACTION: In late morning trading, Intuitive Surgical fell $23.81, or about 5.4%, to $415.19 on heavy trading volume. The shares are down approximately 28% over the past twelve months. OTHERS TO WATCH: Intuitive Surgicalís competitors include Stryker (SYK), Bovie Medical (BVX), and Harvard Apparatus (HART).
News For ISRG;SYK;BVX;HART From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 23, 2015
10:47 EDTISRGIntuitive Surgical CEO says 'probably not leading indicator' of total admissions
Subscribe for More Information
November 17, 2015
10:02 EDTSYKHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use